ライフサイエンスコーパス: soft tissue sarcoma

1 future studies of doxorubicin in metastatic soft tissue sarcoma.

2 ved no prior systemic therapy for metastatic soft tissue sarcoma.

3 our institution for a surgical procedure for soft tissue sarcoma.

4 nes, as well as in tumors from patients with soft tissue sarcoma.

5 s trabectedin exhibited efficacy in advanced soft tissue sarcoma.

6 ry subunit of PP2A, is associated with human soft tissue sarcoma.

7 ination in children and adults with advanced soft tissue sarcoma.

8 el have activity in patients with metastatic soft tissue sarcoma.

9 ogenesis, we have generated a mouse model of soft tissue sarcoma.

10 epithelial cancer, but not in this model of soft tissue sarcoma.

11 eatment of choice for patients with advanced soft tissue sarcoma.

12 utrophils in an autochthonous mouse model of soft tissue sarcoma.

13 Liposarcoma is the most common soft tissue sarcoma.

14 ochthonous mouse model of Kras(G12D) -driven soft tissue sarcoma.

15 ositive association between this variant and soft tissue sarcoma.

16 n effective treatment strategy for childhood soft tissue sarcoma.

17 18 (41%) had bone sarcoma, and 26 (59%) had soft tissue sarcoma.

18 nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma.

19 nostic performance in detection of recurrent soft-tissue sarcoma.

20 esting a potential shift in the treatment of soft-tissue sarcoma.

21 lin could be a treatment option for advanced soft-tissue sarcoma.

22 bility of eribulin in advanced or metastatic soft-tissue sarcoma.

23 rcoma metastasis in a primary mouse model of soft-tissue sarcoma.

24 icin in patients with advanced or metastatic soft-tissue sarcoma.

25 llows reliable and accurate local staging of soft-tissue sarcoma.

26 newly diagnosed lymphoma, neuroblastoma, or soft-tissue sarcoma.

27 n profiles in 608 tumours across subtypes of soft-tissue sarcoma.

28 treatment option for patients with advanced soft-tissue sarcoma.

29 coma of the liver, or unclassified malignant soft-tissue sarcoma.

30 bdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma.

31 treatment in patients with locally advanced soft-tissue sarcoma.

32 treatment for locally advanced or metastatic soft-tissue sarcoma.

33 arcoma (RMS) is the most prevalent pediatric soft-tissue sarcoma.

34 ne treatment for most patients with advanced soft-tissue sarcoma.

35 st-line treatment for advanced or metastatic soft-tissue sarcoma.

36 peripheral nerve sheath tumor, an aggressive soft-tissue sarcoma.

37 ary thyroid carcinoma, and 13% for secondary soft-tissue sarcoma.

38 on and metastasis of many cancers, including soft tissue sarcomas.

39 amous cell carcinomas, mast cell tumors, and soft tissue sarcomas.

40 inical trial involving localized, high-risk, soft tissue sarcomas.

41 tromal tumors (GISTs) are rare but treatable soft tissue sarcomas.

42 apy on survival has been minimal in advanced soft tissue sarcomas.

43 nd may be confused with nonmyogenic, non-RMS soft tissue sarcomas.

44 remains the standard treatment for advanced soft tissue sarcomas.

45 ive chemotherapy for patients with localized soft tissue sarcomas.

46 in tumorigenesis and may aid in diagnosis of soft tissue sarcomas.

47 or types including testicular carcinomas and soft tissue sarcomas.

48 man sarcoma cell lines derived from bone and soft tissue sarcomas.

49 neuroblastoma, Wilms' tumours, and bone and soft tissue sarcomas.

50 trated to be more active compared with other soft tissue sarcomas.

51 S FDA approved for the treatment of advanced soft tissue sarcomas.

52 curative for primary nonmetastatic extremity soft tissue sarcomas.

53 sarcoma (UPS) are highly genetically complex soft tissue sarcomas.

54 maging for determining treatment response in soft-tissue sarcomas.

55 l proliferation/tumorigenesis in a subset of soft-tissue sarcomas.

56 ant fatty tumors, are the second most common soft-tissue sarcomas.

57 ebo plus cisplatin in patients with advanced soft-tissue sarcomas.

58 ment of tumour vascular-disrupting drugs for soft-tissue sarcomas.

59 val in patients after resection of high-risk soft-tissue sarcomas.

60 efit in T-staging of primary bone tumors and soft-tissue sarcomas.

61 ated efficacy in nonleiomyosarcoma histology soft-tissue sarcomas.

62 might improve the treatment and prognosis of soft-tissue sarcomas.

63 topathologic tumor response in patients with soft-tissue sarcomas.

64 factor fusions (TFFs) are present in ~30% of soft-tissue sarcomas.

65 peripheral-nerve tumours, skin cancers, and soft-tissue sarcomas.

66 xorubicin as first-line therapy for advanced soft-tissue sarcomas.

67 ty patients with locally advanced high-grade soft-tissue sarcoma (10 men and 10 women; mean age, 49 +

68 In soft tissue sarcomas, [18F]fluoro-2-deoxy-D-glucose upta

69 arcinoma were breast cancer (5 patients) and soft-tissue sarcoma (2 patients).

70 homa (hazard ratio [95% CI], 3.5 [1.7-7.1]); soft-tissue sarcoma (2.8 [2.1-3.9]); breast carcinoma (2

71 ere Ewing sarcoma family tumors (54%), other soft tissue sarcomas (21%), osteosarcoma (11%), rhabdomy

72 7), breast cancer (4.6; 95% CI, 3.5 to 6.0), soft-tissue sarcoma (3.4; 95% CI, 1.9 to 5.7), thyroid c

73 ostoperative surveillance after resection of soft-tissue sarcoma (35 with high-grade sarcoma) were st

74 geted therapies currently in development for soft tissue sarcomas, a better understanding of the mole

75 tients with chemotherapy-refractory bone and soft-tissue sarcomas according to IGF-1R expression by i

76 It represents the most frequent malignant soft tissue sarcoma affecting the pediatric population a

77 olar rhabdomyosarcomas (ARMS) are aggressive soft-tissue sarcomas affecting children and young adults

78 These cells formed invasive soft tissue sarcomas after i.m. injection into nude or s

79 nced, unresectable, or metastatic high-grade soft-tissue sarcoma, age 18-60 years with a WHO performa

80 rationalizes clinical studies in humans with soft tissue sarcoma, an indication with a notably high u

81 ents aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Gr

82 orrelated with clinical outcomes in Ewing's, soft tissue sarcomas and gastrointestinal stromal tumor.

83 [standard deviation], 45 men) with recurrent soft-tissue sarcoma and 63 age-, sex-, and tumor-matched

84 rapy is beneficial in pre-clinical models of soft-tissue sarcoma and deserves further exploration in

85 and number of previous regimens for advanced soft-tissue sarcoma and in blocks of six.

86 tandard of care for patients with metastatic soft-tissue sarcoma and median overall survival for thos

87 ns a large field of clinical applications in soft-tissue sarcoma and possibly other cancers.

88 nscriptomic marker that identifies high-risk soft-tissue sarcomas and is associated with high metasta

89 ocally advanced, unresectable, or metastatic soft-tissue sarcomas and so this combination cannot be r

90 were noted, including epithelial carcinomas, soft tissue sarcomas, and hematopoietic tumors.

91 on-Hodgkin lymphoma, acute myeloid leukemia, soft-tissue sarcoma, and central nervous system cancer.

92 onfirms the immune subtypes in patients with soft-tissue sarcoma, and unravels the potential of B-cel

93 fficient details to encompass the variety of soft-tissue sarcomas, and available prognostic methods n

94 a, CNS tumours, neuroblastoma, Wilms tumour, soft-tissue sarcomas, and bone cancer) by comparing both

95 en in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatric sarcomas is discusse

96 tcomes for children and adults with advanced soft tissue sarcoma are poor with traditional therapy.

97 Soft tissue sarcomas are a heterogeneous group of tumors

98 ing the preoperative management of extremity soft tissue sarcomas are continuing in an attempt to opt

99 Soft tissue sarcomas are mesenchymal tumors that are fat

100 Soft-tissue sarcomas are heterogeneous cancers that can

101 in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA.

102 croscopically resected, Trojani grade II-III soft-tissue sarcomas at any site, no metastases, perform

103 ative incidence for all SCs combined and for soft tissue sarcomas, bone cancers, and melanoma were ca

104 Liposarcomas are the most common type of soft tissue sarcoma but their genetics are poorly define

105 nse to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patien

106 The Soft Tissue Sarcoma Committee of the Children's Oncology

107 ubsets with different outcomes, allowing the Soft Tissue Sarcoma Committee of the Children's Oncology

108 improves survival of patients with advanced soft-tissue sarcoma compared with doxorubicin alone.

109 ts were treated according to the Cooperative Soft Tissue Sarcoma (CWS) trial protocols.

110 entered 10,000 patients into our prospective soft tissue sarcoma database.

111 ard to the management of these patients with soft tissue sarcomas: delays in diagnosis, trial availab

112 habdomyosarcoma, synovial sarcoma, and adult soft tissue sarcomas diagnosed in adolescents and young

113 Approximately 30% of patients with soft-tissue sarcoma die from pulmonary metastases.

114 ancer, and in a mouse model of autochthonous soft-tissue sarcoma driven by a G12D mutation in KRAS an

115 therapeutic options are needed for bone and soft tissue sarcomas, especially for patients with metas

116 Angiosarcoma (AS) is a rare understudied soft tissue sarcoma exhibiting endothelial cell differen

117 and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an

118 Genetic aberrations responsible for soft-tissue sarcoma formation in adults are largely unkn

119 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma found in children and young adults.

120 gradual migration in the local treatment of soft tissue sarcomas from amputation and similar radical

121 Synovial sarcoma is an aggressive soft tissue sarcoma genetically defined by the fusion on

122 17 of 54 patients in the IGF-1R-positive soft-tissue sarcoma group (31%; one-sided 95% CI lower b

123 activated partial thromboplastin time in the soft-tissue sarcoma group (three [7%] each).

124 e additional patients in the IGF-1R-positive soft-tissue sarcoma group (total of 57 patients) and nin

125 the bone sarcoma group and four [10%] in the soft-tissue sarcoma group) had treatment-emergent seriou

126 e of three treatment groups: IGF-1R-positive soft-tissue sarcoma (group A), IGF-1R-positive bone sarc

127 comas (group B), or IGF-1R-negative bone and soft-tissue sarcoma (group C).

128 Seven (18%) of 40 patients with soft-tissue sarcoma had an objective response, including

129 Patients with soft-tissue sarcoma had to be aged 18 years or older to

130 treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin.

131 Standard therapy for advanced soft-tissue sarcoma has not changed substantially in dec

132 omyosarcoma (RMS), the most common pediatric soft-tissue sarcoma, has two major histological subtypes

133 osensitive tumors compared to other types of soft tissue sarcomas, however, prognosis for advanced re

134 erexpression of MMP-1 and MMP-8 in the human soft tissue sarcoma HSTS26T leads to a significant deple

135 (LMS) is one of the most common subtypes of soft tissue sarcoma in adults and can occur in almost an

136 S/DDLS) account for approximately 13% of all soft tissue sarcoma in adults and cause substantial morb

137 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and represents a high-gr

138 Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children that shares many feature

139 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children.

140 eatment of rhabdomyosarcoma, the most common soft tissue sarcoma in children.

141 Rhabdomyosarcoma is the most common soft tissue sarcoma in the pediatric population.

142 can be used to generate multiple subtypes of soft tissue sarcomas in mice.

143 Rhabdomyosarcoma (RMS) is the commonest soft-tissue sarcoma in childhood and is characterized by

144 oping skeletal muscle and is the most common soft-tissue sarcoma in children and adolescents.

145 habdomyosarcomas (RMS) are the most frequent soft-tissue sarcoma in children and characteristically s

146 skeletal muscle lineage, is the most common soft-tissue sarcoma in children.

147 n, showed clinical activity against advanced soft-tissue sarcoma in phase 1 studies.

148 ival and distant metastases in patients with soft-tissue sarcoma in their extremities.

149 therapy options for patients with metastatic soft-tissue sarcomas in the United States, after a gap o

150 I, 2.3% to 4.8%), whereas body and extremity soft-tissue sarcoma incidence was rare until age 30, whe

151 also highly unstable in three of eight ALT+ soft tissue sarcomas, indicating that somatic destabiliz

152 oblastomas (IRR = 2.34, 95% CI: 1.21, 4.16), soft-tissue sarcomas (IRR = 2.12, 95% CI: 1.09, 3.79), a

153 only approved targeted therapy for advanced soft tissue sarcoma is pazopanib.

154 Although a subset of soft tissue sarcomas is characterized by simple karyotyp

155 e role of the Hippo pathway effector YAP1 in soft tissue sarcomas is poorly defined.

156 igation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.

157 cy to be marketed for advanced or metastatic soft tissue sarcoma) is being explored.

158 g from mesenchymal tissues, such as bone and soft-tissues sarcomas, is still largely unclear.

159 for adolescent and young adult patients with soft tissue sarcomas lag behind those of children diagno

160 on (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10 cm, G2 48.3%, G

161 his review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma.

162 b with doxorubicin in patients with advanced soft-tissue sarcoma met its predefined primary endpoint

163 Of 105 bone and 124 soft-tissue sarcomas, more than one half occurred in the

164 ee, and overall survival among patients with soft-tissue sarcoma, most of whom had received at least

165 diagnosis of locally advanced or metastatic soft-tissue sarcoma not previously treated with an anthr

166 t outcome in paediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), but no risk stratification

167 e conducted analyses separately for bone and soft-tissue sarcomas occurring in the head and neck (in/

168 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence.

169 Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence.

170 omyosarcoma (ARMS) is one of the most common soft tissue sarcoma of childhood, yet the outcome for th

171 l muscle differentiation, is the most common soft tissue sarcoma of childhood.

172 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of skeletal muscle origin in childre

173 chymally transformed breast cancer cells and soft tissue sarcomas of diverse histological subtypes.

174 Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity) study are appropr

175 Rhabdomyosarcoma (RMS) is a common soft-tissue sarcoma of childhood in need of more effecti

176 ases in patients after surgical resection of soft-tissue sarcoma of the extremities.

177 ults (aged >=18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of a

178 produce excellent results, such as bone and soft-tissue sarcoma of the skull base, head and neck, an

179 lly confirmed locally advanced or metastatic soft-tissue sarcoma of Trojani grade 2 or 3, disease pro

180 Angiosarcomas are rare soft-tissue sarcomas of endothelial cell origin that hav

181 is of an advanced unresectable or metastatic soft-tissue sarcoma, of intermediate or high grade, for

182 t among survivors of CNS tumors and bone and soft tissue sarcomas on strength testing (score +/- SD:

183 el, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma from 12 academic cen

184 afety and activity in patients with advanced soft-tissue sarcoma or bone sarcoma.

185 hese three groups contained either recurrent soft-tissue sarcomas or positive postoperative findings

186 dgkin lymphoma, kidney tumor, neuroblastoma, soft-tissue sarcoma, or malignant bone tumor before the

187 ; colorectal; non-Hodgkin lymphoma; thyroid; soft-tissue sarcoma; ovarian; bladder; other female geni

188 ially increased risks of subsequent bone and soft-tissue sarcomas, particularly after radiotherapy.

189 a defective p53 response, we found that male soft tissue sarcoma patients carrying the minor T allele

190 Several phase II trials in advanced soft tissue sarcoma patients have investigated the effic

191 vide modest benefit overall to nonadipocytic soft tissue sarcoma patients, but we have yet to identif

192 We present data from a pilot study in 10 soft-tissue sarcoma patients imaged with (11)C-thymidine

193 In soft-tissue sarcoma patients, we find that the alleles o

194 e of histologic type in radiation-associated soft tissue sarcomas (RASs) and determine whether RASs a

195 total of 53 patients with advanced non-GIST soft tissue sarcomas received sunitinib 37.5 mg daily.

196 sion-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard

197 has recently been approved for nonadipocytic soft tissue sarcomas refractory to chemotherapy.

198 juvant chemotherapy on survival for resected soft-tissue sarcoma remains unknown.

199 Soft tissue sarcomas represent a diverse group of tumors

200 Soft-tissue sarcomas represent a heterogeneous group of

201 ti-platform molecular landscape of 206 adult soft tissue sarcomas representing 6 major types.

202 hat the Hippo pathway is deregulated in many soft-tissue sarcomas, resulting in elevated expression o

203 Strikingly elevated bone and soft-tissue sarcoma risks differ by age, location, and s

204 the conventional staging of retroperitoneal soft tissue sarcomas (RPS) is essential in providing eff

205 o investigate the genetic basis for bone and soft-tissue sarcoma seen in routine clinical practice.

206 with doxorubicin and ifosfamide in resected soft-tissue sarcoma showed no benefit in relapse-free su

207 and neck carcinoma occurred in survivors of soft tissue sarcoma (SIR = 22.6), neuroblastoma (SIR = 2

208 est following neuroblastoma (SIR = 24.2) and soft tissue sarcoma (SIR = 6.2).

209 renal cancer (SIR, 3.9; 95% CI, 2.0 to 7.5), soft tissue sarcoma (SIR, 2.6; 95% CI, 1.5 to 4.4), and

210 to 2,873 v SIR, 169; 95% CI, 115 to 239) and soft-tissue sarcomas (SIR, 542; 95% CI, 418 to 692 v SIR

211 However, for 4 deaths of soft tissue sarcoma (SMR = 4.1, 95% CI: 1.1, 10.5), the

212 In this presumed first prospective trial of soft tissue sarcoma spanning nearly the entire age spect

213 We applied this approach to 52 childhood soft tissue sarcoma specimens in an attempt to identify

214 and poly(ADP-ribose) polymerase cleavage in soft tissue sarcoma (STS) cells.

215 Randomized controlled trials (RCTs) in soft tissue sarcoma (STS) have used varying end points.

216 to guide the multidisciplinary management of soft tissue sarcoma (STS) of the extremities, controvers

217 radiation therapy (IMRT) in the treatment of soft tissue sarcoma (STS) of the extremity is increasing

218 din-mimetic mechanism, suggested activity in soft tissue sarcoma (STS) patients.

219 he American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging system is more accurat

220 therapy in patients with first-line advanced soft tissue sarcoma (STS) to assess progression-free sur

221 s late toxicities in patients with extremity soft tissue sarcoma (STS) treated with preoperative imag

222 n (9-NC) in patients with advanced chordoma, soft tissue sarcoma (STS), and gastrointestinal stromal

223 Here, in a study of 18 canine patients with soft tissue sarcoma (STS), CIVO captured complex, patien

224 lung, such as renal cell carcinoma (RCC) and soft tissue sarcoma (STS), have an inherent capacity to

225 Using a murine model of soft tissue sarcoma (STS), we show that disruption of th

226 d trabectedin are considered active drugs in soft tissue sarcoma (STS).

227 ngs progression-free survival in adults with soft tissue sarcoma (STS).

228 ant chemotherapy (CT) in high-risk extremity soft tissue sarcoma (STS).

229 f care in patients with advanced, inoperable soft tissue sarcoma (STS).

230 ns for children with high-risk nonmetastatic soft tissue sarcoma (STS).

231 The AKT signaling pathway is activated in soft tissue sarcoma (STS).

232 f surgical center case volume on outcome for soft tissue sarcoma (STS).

233 Soft tissue sarcomas (STS) have a strong propensity for

234 nocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, an

235 in and pathogenesis of the majority of adult soft tissue sarcomas (STS) remains poorly understood.

236 currence rates for selected patients with T1 soft tissue sarcomas (STS) treated by surgery alone.

237 In soft tissue sarcomas (STS), low intratumoural O2 (hypoxi

238 e pre-clinical activity of ATR inhibition in soft tissue sarcomas (STS).

239 ET and CT response criteria in patients with soft-tissue sarcoma (STS) after combined chemotherapy pl

240 to determine if such concern is warranted in soft-tissue sarcoma (STS) of the extremity.

241 Background Managing soft-tissue sarcoma (STS) relies on histologic grade, wh

242 Some patients with soft-tissue sarcoma (STS) report a history of injury at

243 r predicting the histopathologic response of soft-tissue sarcoma (STS) to neoadjuvant isolated limb p

244 Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies o

245 Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inab

246 Human soft-tissue sarcomas (STS) are rare mesenchymal tumors w

247 olated limb perfusion (ILP) in patients with soft-tissue sarcomas (STS).

248 Soft tissue sarcomas (STSs) are mesenchymal tumours wher

249 the activity of BMS-247550 in patients with soft tissue sarcomas (STSs) who had not received prior c

250 an inferior prognosis compared with sporadic soft tissue sarcomas (STSs).

251 ally engineered autochthonous mouse model of soft-tissue sarcomas (STSs) to determine NG2/CSPG4's rol

252 therlands, who were enrolled in the European Soft Tissue Sarcoma Study Group (E pSSG) RMS 2005 study.

253 The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investi

254 In 2005, the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) proposed a conse

255 Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype.

256 Genomic profiling of soft tissue sarcomas subtypes reveals a propensity for t

257 ion reduced tumor burden in a mouse model of soft-tissue sarcoma, suggesting that p53 strongly inhibi

258 Synovial sarcoma, a soft tissue sarcoma that develops in adults, is patholog

259 (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogen

260 Liposarcoma is a type of soft tissue sarcoma that exhibits poor survival and a hi

261 e in a genetically engineered mouse model of soft tissue sarcoma that loss of GCN2 has no effect on t

262 peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that arise in connective tissue sur

263 ve sheath tumors (MPNST) are highly invasive soft tissue sarcomas that arise within the peripheral ne

264 LOH analysis of 160 cases of RMS and non-RMS soft tissue sarcomas that is at variance with convention

265 of care for adults who have the subtypes of soft tissue sarcomas that typically occur in pediatric p

266 Synovial sarcoma (SS) is an aggressive soft-tissue sarcoma that is often discovered during adol

267 Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy

268 habdomyosarcomas (ARMS) are highly malignant soft-tissue sarcomas that arise in children, adolescents

269 peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas that frequently arise in patients w

270 NSTs) represent a group of highly aggressive soft-tissue sarcomas that may occur sporadically, in ass

271 With the exception of soft tissue sarcoma, the authors found little evidence o

272 At present for soft-tissue sarcomas, the 5-y survival is approximately

273 In rhabdomyosarcoma (RMS), a pediatric soft-tissue sarcoma thought to arise from myogenic precu

274 ologic response of osteosarcoma, Ewing's and soft tissue sarcomas to chemotherapy, and has correlated

275 t clinical benefit in patients with advanced soft-tissue sarcomas to support its use as a therapeutic

276 toperative Radiotherapy in Curable Extremity Soft Tissue Sarcoma) trial receiving preoperative radiat

277 in and ifosfamide for palliation of advanced soft-tissue sarcoma unless the specific goal is tumour s

278 t malignant neoplasms, particularly bone and soft tissue sarcomas, uterine leiomyosarcoma, melanomas,

279 Although representing only 1% to 2% of soft tissue sarcomas, vascular sarcomas provide unique i

280 , and T1-weighted MRI) from 51 patients with soft-tissue sarcoma was used to prospectively assess rep

281 clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infu

282 Subcutaneous soft tissue sarcomas were labeled with the highest fluor

283 All other types of soft tissue sarcomas were negative for perilipin 1.

284 95% CI, 1.23 to 7.16), but risks for bone or soft tissue sarcomas were not elevated.

285 ive radiotherapy for patients with extremity soft tissue sarcomas were recently presented at the 2004

286 istologically confirmed diagnosis of bone or soft-tissue sarcoma were allocated on the basis of IGF-1

287 Preoperative MR images in 174 patients with soft-tissue sarcoma were analyzed by two readers.

288 ocally advanced, unresectable, or metastatic soft-tissue sarcoma were screened.

289 eterogeneity, and peritumoral enhancement of soft-tissue sarcomas were associated with grade III tumo

290 Head and neck bone and soft-tissue sarcomas were diagnosed beginning in early c

291 rential diagnosis of liposarcomas from other soft tissue sarcomas, whereas perilipin 2 correlates neg

292 ed trunk or extremity chemotherapy-sensitive soft tissue sarcoma, which were larger than 5 cm in diam

293 Soft-tissue sarcomas, which result in approximately 10,7

294 us tissue damage, in patients with extremity soft tissue sarcomas who receive once-daily preoperative

295 ival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in p

296 MR imaging examinations in 23 patients with soft-tissue sarcomas who had undergone neoadjuvant thera

297 A retrospective study of patients with soft-tissue sarcomas who were imaged from January 2009 t

298 d-cell tumors (DSRCT), a rare but aggressive soft tissue sarcoma with a high rate of mortality.

299 Rhabdomyosarcoma is a soft-tissue sarcoma with molecular and cellular features

300 habdomyosarcoma is the most common childhood soft-tissue sarcoma, yet patients with metastatic or rec